Ontology highlight
ABSTRACT: Background
Whether an oxaliplatin- or cisplatin-based regimen is more optimal for treating elderly patients with advanced gastric cancer, in terms of survival and adverse events remains unclear.Methods
In this retrospective cohort study, we used stacked claim data of residents in two Japanese prefectures collected between 2012 and 2017 and between 2014 and 2019, respectively. We included patients with advanced gastric cancer who received oxaliplatin-based and cisplatin-based regimens. Propensity score overlap weighting analysis was conducted to compare overall survival and granulocyte colony-stimulating factor use during chemotherapy between the oxaliplatin- and cisplatin-based treatment groups.Results
A total of 242 patients were included in the study. After propen
SUBMITTER: Chinen T
PROVIDER: S-EPMC9044765 | biostudies-literature | 2022 Apr
REPOSITORIES: biostudies-literature